HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA Vaccines
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been advised by the Office of the Biomedical Advanced Research and Development Authority (BARDA) that the Request for Proposal (RFP)...
Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business
Emergent BioSolutions Inc. (NYSE:EBS) is pleased to announce the appointment of Steven Chatfield, Ph.D. as Senior Vice President, Biodefense effective immediately. Dr. Chatfield rejoins the Company...
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the months of December 2009 and January...
Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009
Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30,...
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the month of November...
Emergent BioSolutions Sponsors Security and Defence Agenda Roundtable on Biopreparedness
Emergent BioSolutions Inc. (NYSE:EBS) was pleased to sponsor the Security and Defence Agenda’s (SDA) roundtable discussion, “Raising Biopreparedness Levels in Europe,” which examined European...
Emergent BioSolutions to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009
Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for third quarter 2009 on Thursday, November 5, 2009, after market...
NIAID to Fund Development of Emergent BioSolutions’ Advanced Anthrax Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National...
Emergent BioSolutions Issues Statement on Court Ruling
Emergent BioSolutions Inc. (NYSE:EBS) released the following statement today relating to its efforts to collect on the debt owed to it by Protein Sciences Corporation (PSC) through the filing of an...
Emergent BioSolutions to Webcast Presentation at Upcoming Investor Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conference during the month of September...
Emergent BioSolutions Expands Manufacturing and Development Infrastructure Through a Series of Real Estate Transactions
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into multiple real estate transactions that will expand the Company's manufacturing and development infrastructure. These...